Compugen, Ltd

Author: Zangvil, Eli

Source: Pharmacogenomics, Volume 8, Number 10, October 2007 , pp. 1461-1463(3)

Buy & download fulltext article:

Price: $63.00 plus tax (Refund Policy)

Abstract:

Compugen's mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industry. The Company's powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. This capability results from the Company's decade-long pioneering efforts in the deeper understanding of important biological phenomena at the molecular level through the incorporation of ideas and methods from mathematics, computer science and physics into biology, chemistry and medicine. To date, Compugen's product discovery efforts and its initial discovery engines have focused mainly on the areas of cancer, immune-related and cardiovascular diseases. The Company's primary commercialization pathway for its product candidates is to enter into milestone and revenue sharing out-licensing and joint development agreements with leading therapeutic and diagnostic companies.

Keywords: diagnostic marker; disease predisposition; drug discovery; drug response; genomic marker; genomic variation; genotyping; SNP; therapeutics

Document Type: Research article

DOI: http://dx.doi.org/10.2217/14622416.8.10.1461

Affiliations: 1: Compugen Ltd, 72 Pinchas Rosen, Tel Aviv 69512, Israel., Email: eli.zangvil@cgen.com

Publication date: 2007-10-01

More about this publication?

Pharmacogenomics provides the community with an essential resource for keeping abreast of the latest developments in new pharmacogenomic initiatives, emerging technologies for accessing genomic information and the development of novel diagnostic products and strategies.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites